Hypothesis

Long‑term pharmacological blockade of nociceptive signaling (e.g., NSAIDs, opioids, TRPV1 antagonists) diminishes a hormetic stress cascade that normally activates pro‑longevity pathways, thereby shortening lifespan and accelerating cellular aging.

Mechanistic Basis

• Sensory neurons release neuropeptides such as CGRP and substance P when activated by mild noxious stimuli. These peptides act on peripheral tissues to stimulate the IGF‑1/AKT pathway in a transient, pulsatile manner, which in turn triggers FOXO nuclear translocation and up‑regulation of stress‑response genes (e.g., sod‑3, hsp‑16.2) [[https://elifesciences.org/articles/62659]].
• In C. elegans, cool‑temperature activation of TRPA‑1 drives a glutamate‑serotonin circuit that promotes DAF‑16/FOXO activity in the intestine [[https://pmc.ncbi.nlm.nih.gov/articles/PMC5859961/]]. Analogous TRPV1‑dependent signaling in mammals likely converges on similar FOXO‑centric transcription programs.
• With age, endogenous neuroendocrine peptides like DAF‑7 (the worm homolog of TGF‑β) decline, reducing sensitivity to longevity‑extending cues [[https://journals.plos.org/plosgenetics/article?id=10.1371%2Fjournal.pgen.1006544]]. Pharmacological silencing of nociception would exacerbate this decline by removing an upstream activator of DAF‑7‑like signaling.
• Food‑derived sensory cues modulate longevity via INS‑6, which inhibits DAF‑16/FOXO when nutrition is abundant [[https://pmc.ncbi.nlm.nih.gov/articles/PMC4863736/]]. Nociceptive input normally opposes this inhibition, creating a bistable switch that favors repair during periods of low‑level stress. Analgesics lock the system in the fed, growth‑promoting state, attenuating repair.

Testable Predictions

1. Mice treated chronically with low‑dose ibuprofen or morphine will show reduced intestinal FOXO nuclear localization and lower expression of sod‑2 and hsp70 compared with vehicle controls.
2. Genetic ablation of TRPV1 in sensory neurons will shorten lifespan under standard conditions but will not further reduce lifespan when combined with analgesic treatment, indicating epistasis.
3. Transient, low‑intensity capsaicin exposure (activating TRPV1 without causing tissue damage) will extend lifespan in wild‑type mice; this extension will be blocked by concurrent TRPV1 antagonism.
4. In humans, retrospective cohorts of long‑term NSAID users will exhibit elevated plasma markers of oxidative stress (e.g., 8‑iso‑PGF2α) and shorter leukocyte telomere length after adjusting for age, comorbidities, and pain severity.

Experimental Approach

• Model organism: Use C. elegans strains expressing fluorescent DAF‑16::GFP and a TRPA‑1::mCherry reporter. Treat adult worms with FDA‑approved analgesics (e.g., naproxen, morphine) at concentrations that block chemosensory avoidance without causing lethality. Quantify DAF‑16 nuclear translocation, stress‑gene reporter activity, and lifespan.
• Vertebrate model: Administer chronic ibuprofen (50 mg/kg/day) or sustained‑release morphine to C57BL/6 mice from 6 months of age. Monitor fasting glucose, IGF‑1 levels, intestinal FOXO immunostaining, and perform survival analysis.
• Human data: Extract prescription records from a large EHR database (e.g., UK Biobank) to identify individuals with ≥2 years of continuous NSAID or opioid prescriptions. Match controls on age, sex, BMI, baseline pain scores, and cardiovascular risk. Compare longitudinal changes in leukocyte telomere length and incident age‑related diseases.

Potential Confounds and Mitigation

• Analgesics may affect lifespan via off‑target effects on gut microbiota or cardiovascular function. Include germ‑free or antibiotic‑treated cohorts to isolate neuronal effects.
• Pain severity itself influences morbidity. Stratify analyses by baseline pain scores and incorporate pain‑as‑a‑covariate in statistical models.
• Developmental effects: initiate drug treatment only after reproductive maturity to avoid confounding developmental pathways.

If these experiments confirm that dampening nociceptive signaling curtails FOXO‑driven maintenance, it would reframe analgesics not merely as symptom blockers but as modulators of a conserved neuroendocrine aging axis, urging a more nuanced approach to pain management in older populations.